Long-term persistence of antibodies against hepatitis A and B (anti-HAV and anti-HBs) were evaluated in 1- to 11-year-old children following 2 doses (0, 6 months) of hepatitis A and B vaccine. Ten years postvaccination, all subjects were anti-HAV seropositive (≥15 mIU/mL), 81.7% had anti-HBs antibody concentrations ≥10 mIU/mL. All subjects with anti-HBs concentrations <10 mIU/mL, mounted a vigorous anamnestic response to an HBV vaccine challenge dose indicating the presence of immunologic memory against hepatitis B.
From the *Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (WHO Collaborating Centre), University of Antwerp, Antwerpen, Belgium; and †GlaxoSmithKline Biologicals, Wavre, Belgium.
Accepted for publication February 1, 2011.
GlaxoSmithKline Biologicals was the funding source of the vaccine trial and was involved along with the authors in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals also took in charge of costs associated with the development and the publishing of the present manuscript.
Marie Van Der Wielen is currently at GlaxoSmithKline Biologicals, Wavre, Belgium.
Twinrix and Ambirix are trademarks of the GlaxoSmithKline group of companies. AUSAB-EIA is a registered trademark of Abbott Laboratories, North Chicago; Enzygnost is a registered trademark of DADE Behring, Marburg, Germany.
Address for correspondence: Pierre Van Damme, MD, PhD, Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute (WHO Collaborating Centre), University of Antwerp, Campus Drie Eiken (room R2.14), Universiteitsplein 1, 2610 Antwerpen (Wilrijk), Belgium. E-mail: firstname.lastname@example.org.